Kodiak Sciences Inc. (KOD)
| Market Cap | 5.92B +611.6% |
| Revenue (ttm) | n/a |
| Net Income | -241.99M |
| EPS | -4.18 |
| Shares Out | 62.72M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,676,504 |
| Open | 98.95 |
| Previous Close | 98.46 |
| Day's Range | 88.63 - 98.95 |
| 52-Week Range | 10.94 - 104.00 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 96.33 (+1.99%) |
| Est. Earnings | Nov 12, 2026 |
About KOD
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic mac... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for KOD stock is "Strong Buy." The 12-month stock price target is $96.33, which is an increase of 1.99% from the latest price.
News
Short Report: Kodiak Sciences short interest at record high
Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the…
Kodiak Sciences price target raised to $103 from $36 at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk raised the firm’s price target on Kodiak Sciences (KOD) to $103 from $36 and keeps a Neutral rating on the shares. The firm is citing…
Kodiak Sciences price target raised to $120 from $80 at UBS
UBS analyst Michael Yee raised the firm’s price target on Kodiak Sciences (KOD) to $120 from $80 and keeps a Buy rating on the shares. Kodiak’s Zenkuda data materially strengthen…
Kodiak Sciences price target raised to $112 from $56 at Jefferies
Jefferies raised the firm’s price target on Kodiak Sciences (KOD) to $112 from $56 and keeps a Buy rating on the shares. The firm said that Kodiak’s DAYBREAK Phase III…
Kodiak Sciences price target raised to $145 from $85 at LifeSci Capital
LifeSci Capital raised the firm’s price target on Kodiak Sciences (KOD) to $145 from $85 and keeps an Outperform rating on the shares after the company reported positive topline results…
Kodiak Sciences rises 161.9%
Kodiak Sciences (KOD) is up 161.9%, or $52.36 to $84.71.
Kodiak Sciences price target raised to $96 from $58 at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $96 from $58 and keeps a Buy rating on the shares after the company announced…
Kodiak Sciences Phase 3 press release ‘reads excellent,’ says Evercore ISI
After Kodiak Sciences (KOD) announced that the primary endpoints were met for both Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration, Everc...
Kodiak data raises competitive bar for Regeneron, says Citi
Citi says shares of Regeneron (REGN) are down after Kodiak Sciences’ (KOD) Zenkuda delivered non-inferior vision gains versus aflibercept in a Phase 3 wet age-related macular degeneration study. Regen...
Kodiak Sciences rises 136.7%
Kodiak Sciences (KOD) is up 136.7%, or $44.21 to $76.56.
Kodiak Sciences Transcript: Study result
DAYBREAK Phase III results show Zenkuda and tabirafusp-ted achieved equivalence to aflibercept in visual and anatomic outcomes for wet AMD, with over half of patients on six-month dosing. The AI-driven retreatment closely mirrors real-world practice, and both drugs demonstrated strong safety profiles.
Kodiak Sciences Press release: Study result
Kodiak Sciences issued a press release on September 28, 2026, disclosing material business information to investors.
Kodiak Sciences Slides: Study result
Kodiak Sciences has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Kodiak Sciences says primary endpoints met in Phase 3 DAYBREAK study
Kodiak Sciences (KOD) announced that the primary endpoints were met for both Zenkuda and tabirafusp-ted in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration. The DAYBREA...
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused bio...
Kodiak Sciences resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of Kodiak Sciences (KOD) with a Neutral rating and $36 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform…
3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts
Analysts see strong momentum in some stocks this week, including Kodiak Sciences ($KOD), Archer Aviation ($ACHR), and CleanSpark ($CLSK). While each stock carries risk, analysts believe all three have...
Kodiak Sciences reports Q2 EPS ($1.05), consensus (96c)
Ended Q2 with $125.9M of cash and cash equivalents, expects that current cash and cash equivalents will support current and planned operations into 2027. “Kodiak continues to execute broadly across…
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026.
Kodiak Sciences Earnings release: Q2 2026
Kodiak Sciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Kodiak Sciences Quarterly report: Q2 2026
Kodiak Sciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Kodiak enrolls first patients in phase 3 ALTO trial evaluating KSI-501
Kodiak Sciences (KOD) announces the first patients have been enrolled in the global Phase 3 ALTO trial evaluating KSI-501 in patients with diabetic macular edema, or DME. KSI-501 is an…
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasd...
Kodiak Sciences completes enrollment in first cohort of Phase 3 PEAK trial
Kodiak Sciences (KOD) announced that it has completed enrollment of the first 300-patient cohort in its PEAK trial, supporting Pivotal Analysis 1 of the KSI-101 Phase 3 program in macular…